Loading clinical trials...

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

NCT06333652•Mayo Clinic

Summary

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Eligibility

Age

18 - 50 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Individuals with \< 34 0/7 weeks of gestation.
•Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria

•Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
•Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Locations (1)

Mayo Clinic Minnesota

Rochester, Minnesota, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

December 31, 2026

Completion Date

December 31, 2028

Last Updated

November 12, 2025

Enrollment

ESTIMATED participants

Conditions

Preeclampsia

Interventions

Ravulizumab

DRUG

Contacts

Gonzalez Suarez

CONTACT

507-284-2511

Prevention of Preeclampsia in Denmark: A National Implementation Study

NCT07485140

Preeclampsia (PE)

View study

RECRUITINGEARLY_PHASE1

Vascular Effects of High-Salt After Preeclampsia

NCT06749418

PreeclampsiaPreeclampsia Postpartum

View study

RECRUITINGNA

Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Inclusion Criteria

Exclusion Criteria

Prevention of Preeclampsia in Denmark: A National Implementation Study

Vascular Effects of High-Salt After Preeclampsia

Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy

A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Aspirin and Preeclampsia